<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00583011</url>
  </required_header>
  <id_info>
    <org_study_id>AmniocentesisPain</org_study_id>
    <nct_id>NCT00583011</nct_id>
  </id_info>
  <brief_title>Local Anesthesia and Pain Perception During an Amniocentesis</brief_title>
  <official_title>Local Anesthesia and Pain Perception During Amniocentesis: A Randomized Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is been designed to answer the question of whether local anesthesia (1% lidocaine)&#xD;
      decreases the perception of pain associated with amniocentesis in a randomized double blind&#xD;
      placebo controlled manner. Our objective is to determine the effect of local anesthesia on&#xD;
      the maternal pain perception from an amniocentesis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women meeting criteria for project and agreeing to treatment will be randomized into either&#xD;
      the 1% Lidocaine or placebo(normal saline) group. The initial injection of either 1%&#xD;
      lidocaine or placebo (normal saline) will be administered 2 minutes prior to the&#xD;
      amniocentesis procedure. 2cc of 1% lidocaine or placebo (normal saline) will be initially&#xD;
      administered as an intradermal &quot;wheal&quot;, followed by a deeper infiltration of the 1% lidocaine&#xD;
      or placebo (normal saline) to the depth of the peritoneum. All procedures will be performed&#xD;
      by either the Maternal-Fetal medicine (MFM) or the reproductive geneticist utilizing&#xD;
      continuous ultrasound guidance under sterile conditions. Each woman will be asked to rate&#xD;
      their pain perception immediately after the procedure on two pain scales.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intensity of Perceived Maternal Pain as Measured by the Visual Analogue Scale (VAS)</measure>
    <time_frame>Immediately following amniocentesis procedure</time_frame>
    <description>Visual Analogue Scale (Perpendicular line is drawn at the point that represents pain on a 0-100mm scale, with lower number meaning less pain and the higher number meaning more pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensity of Perceived Maternal Pain as Measured by the 101 Point Numerical Rating Scale (NRS-101)</measure>
    <time_frame>Immediately following amniocentesis procedure</time_frame>
    <description>101 Point Numerical Rating Scale (NRS-101) (Choose a number that best described pain from 0 to 100 with 0 being least amount of pain and 100 being the worst pain)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Local Anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Local anesthesia group. 2cc of 1% lidocaine with epinephrine administered 2 minutes before amniocentesis, using a 21 gauge needle initially as an intradermal wheal followed by a deeper infiltration of 2cc of 1% lidocaine to the depth of the peritoneum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo normal saline group. 2cc of normal saline epinephrine administered 2 minutes before amniocentesis, using a 21 gauge needle initially as an intradermal wheal followed by a deeper infiltration of 2cc of normal saline to the depth of the peritoneum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Local Anesthesia</intervention_name>
    <description>Local anesthesia: 2 cc of 1% Lidocaine</description>
    <arm_group_label>Local Anesthesia</arm_group_label>
    <other_name>Amniocentesis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Group</intervention_name>
    <description>Placebo Group: 2cc Normal Saline</description>
    <arm_group_label>Placebo-Normal saline</arm_group_label>
    <other_name>Amniocentesis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Singleton pregnancies&#xD;
&#xD;
          -  Signed consent to participate in the trial&#xD;
&#xD;
          -  Women between the ages of 18 and 45 years&#xD;
&#xD;
          -  Gestational ages 15 - 24 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple gestation&#xD;
&#xD;
          -  Refusal to participate in the trial&#xD;
&#xD;
          -  Known hypersensitivity to lidocaine&#xD;
&#xD;
          -  Amniocentesis during this pregnancy&#xD;
&#xD;
          -  Amnioinfusion/amnioreduction where the procedure is likely to be prolonged&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Elimian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2007</study_first_posted>
  <results_first_submitted>October 15, 2020</results_first_submitted>
  <results_first_submitted_qc>January 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 3, 2021</results_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amniocentesis</keyword>
  <keyword>Genetic amniocentesis</keyword>
  <keyword>Fetal lung maturity</keyword>
  <keyword>Pain control</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>High risk pregnancy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Assessed for eligibility (n=203) Excluded=127(26 not meeting inclusion criteria, 101 declined to participate)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lidocaine</title>
          <description>Local anesthesia group&#xD;
Local anesthesia - lidocaine: Local anesthesia: 2 cc of 1% Lidocaine</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo normal saline group&#xD;
Placebo Group: Placebo Group: 2cc Normal Saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lidocaine</title>
          <description>Lidocaine group 2cc of 1% lidocaine</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Normal saline group 2cc of normal saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.3" spread="6.5"/>
                    <measurement group_id="B2" value="30.1" spread="7.5"/>
                    <measurement group_id="B3" value="30.7" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intensity of Perceived Maternal Pain as Measured by the Visual Analogue Scale (VAS)</title>
        <description>Visual Analogue Scale (Perpendicular line is drawn at the point that represents pain on a 0-100mm scale, with lower number meaning less pain and the higher number meaning more pain)</description>
        <time_frame>Immediately following amniocentesis procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>Lidocaine 2cc of 1% lidocaine group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2cc of Normal Saline group</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of Perceived Maternal Pain as Measured by the Visual Analogue Scale (VAS)</title>
          <description>Visual Analogue Scale (Perpendicular line is drawn at the point that represents pain on a 0-100mm scale, with lower number meaning less pain and the higher number meaning more pain)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="2.1" upper_limit="21.0"/>
                    <measurement group_id="O2" value="18.4" lower_limit="12.9" upper_limit="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensity of Perceived Maternal Pain as Measured by the 101 Point Numerical Rating Scale (NRS-101)</title>
        <description>101 Point Numerical Rating Scale (NRS-101) (Choose a number that best described pain from 0 to 100 with 0 being least amount of pain and 100 being the worst pain)</description>
        <time_frame>Immediately following amniocentesis procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>Lidocaine 2cc of 1% lidocaine group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>2 cc of Normal saline group</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of Perceived Maternal Pain as Measured by the 101 Point Numerical Rating Scale (NRS-101)</title>
          <description>101 Point Numerical Rating Scale (NRS-101) (Choose a number that best described pain from 0 to 100 with 0 being least amount of pain and 100 being the worst pain)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" spread="13.5"/>
                    <measurement group_id="O2" value="22.4" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>No adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>Lidocaine</title>
          <description>Lidocaine 2cc of 1% lidocaine group</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>2cc of Normal saline group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Elimian, MD</name_or_title>
      <organization>University of Oklahoma Health Science Center</organization>
      <phone>9142317323</phone>
      <email>aelimian@aol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

